

Table S7. Patient baseline demographic and disease characteristics in the del(17p) and/or TP53 gene mutated patient subpopulations from the OCEAN trial.

Baseline demographics

	Melflufen - TP53 mutant, N=15	Melflufen - TP53 wild type , N=62	Pomalidomide - TP53 mutant, N=18	Pomalidomide - TP53 wild type, N=50
Age	66 (51-80)	65 (41-84)	68 (43-83)	68 (46-80)
Agegroup				
<65	6 (40.0)	28 (45.2)	6 (33.3)	14 (28.0)
65-74	8 (53.3)	27 (43.5)	9 (50.0)	27 (54.0)
75+	1 (6.7)	7 (11.3)	3 (16.7)	9 (18.0)
Male	6 (40)	32 (52)	9 (50)	25 (50)
Race				
WHITE	15 (100.0)	55 (88.7)	15 (83.3)	44 (88.0)
BLACK OR AFRICAN AMERICAN	0 (0.0)	0 (0.0)	1 (5.6)	1 (2.0)
ASIAN	0 (0.0)	4 (6.5)	2 (11.1)	3 (6.0)
NATIVE HAWAIIAN OR OTHER PACIFIC ISLANDER	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
OTHER	0 (0.0)	1 (1.6)	0 (0.0)	0 (0.0)
NOT REPORTED	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
UNKNOWN	0 (0.0)	2 (3.2)	0 (0.0)	2 (4.0)

Disease characteristics

	Melflufen - TP53 mutant, N=15	Melflufen - TP53 wild type , N=62	Pomalidomide - TP53 mutant, N=18	Pomalidomide - TP53 wild type, N=50
Years from diagnosis, median (range)	4.5 (1.5-8.4)	4.6 (0.5-17.8)	4.3 (1.2-12.5)	4.4 (0.4-13.7)
Prior treatment regimens, median (range)	3 (2-4)	3 (2-4)	3 (2-4)	3 (2-4)
Documented refractory status, n(%)				
Lenalidomide	15 (100)	62 (100)	18 (100)	50 (100)
Pomalidomide	0 (0)	0 (0)	0 (0)	0 (0)
Bortezomib	11 (73)	30 (48)	10 (56)	22 (44)
Carfilzomib	0 (0)	6 (10)	3 (17)	7 (14)
Daratumumab	1 (7)	14 (23)	2 (11)	7 (14)
Alkylator refractory, n(%)	6 (40)	25 (40)	6 (33)	8 (16)
Melphalan exposed	5 (33)	11 (18)	7 (39)	15 (30)
Melphalan refractory	2 (13)	5 (8)	2 (11)	3 (6)
Previous stem cell transplant, n(%)	9 (60)	33 (53)	10 (56)	29 (58)
International Staging System at Baseline, n(%)				
I	6 (40)	37 (60)	4 (22)	31 (62)
II	7 (47)	18 (29)	13 (72)	15 (30)
III	2 (13)	7 (11)	1 (6)	4 (8)
High-risk cytogenetics, n(%)	13 (87)	16 (26)	14 (78)	18 (36)
Extramedullary disease (EMD), n(%)	1 (7)	14 (23)	2 (11)	4 (8)
ECOG at baseline, n(%)				
0	6 (40)	21 (34)	4 (22)	20 (40)
1	6 (40)	32 (52)	12 (67)	26 (52)
2	3 (20)	9 (15)	2 (11)	4 (8)
TTP following ASCT				
No transplant	6 (40)	29 (47)	8 (44)	21 (42)
<1y	3 (20)	4 (6)	4 (22)	6 (12)
1-2y	4 (27)	15 (24)	3 (17)	19 (38)
2-3y	1 (7)	7 (11)	2 (11)	3 (6)
>3y	1 (7)	7 (11)	1 (6)	1 (2)